Form D · Biotechnology

Prolocor Inc.

Philadelphia, PA · CIK 0001879794

Offering snapshot reported Jan 31, 2022 · SEC filing

Reported sold
$1.57M
Offering amount: $3M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 19, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$786K$1.57MAug 25, 2021: $722,500.00Aug 25, 2021Jan 31, 2022: $1,572,000.00Jan 31, 2022

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$722,500 → $1,572,000

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 31, 2022Amendment$1,572,000$849,500vs Aug 25, 202111SEC filing
Aug 25, 2021Initial$722,500No comparisonNot reportedSEC filing

Offering details

Securities
Debt, Security to be acquired
Exemptions
04.3
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-411169

Source: Form D, filed Jan 31, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Peter M. Di Battiste Director, Executive
David Schneider Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2138 Lombard Street Unit 4 A
Philadelphia, PA, 19146